MondayJun 06, 2022 1:53 pm

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Announced Addition to Russell 2000(R), 3000(R) Indexes

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, will be joining the Russell 2000 and 3000® Indexes effective later this month, on June 27, 2022, after the market opens. The company was named on a preliminary list of additions posted by FTSE Russell on June 3, 2022. In addition, MULN will be automatically added to the appropriate growth and value indexes. According to the announcement, the Russell indexes are comprised of the 4,000 largest U.S. stocks, based on May 6, 2022, trading status. Membership is for one year and is reassessed every year, with new members released annually. Membership…

Continue Reading

MondayJun 06, 2022 1:39 pm

TinyGemsBreaks – Tingo Inc. (TMNA) Reports on Annual Shareholder Meeting Results

Tingo (OTC: TMNA), a leading agri-fintech business in Africa, held its Annual Meeting of Stockholders last week. The meeting, which convened on June 2, 2022, had three agenda items, including the election of director nominees. The report noted that shareholders elected 10 director nominees for one-year terms. The nominees include Adewale Adebayo, John J. Brown, Christophe Francois Charlier, Christopher Cleverly, Gurjinder Johal, Leslie Kasumba, Dozy Mmobuosi, Onyekachi Onubogu, Dakshesh Patel and Derrick Randall. In addition, shareholders unanimously ratified the appointment of Gries & Associates LLC as Tingo’s independent accountants for the 2022 fiscal year and approved the compensation paid to the…

Continue Reading

MondayJun 06, 2022 1:11 pm

TinyGemsBreaks – SRAX Inc. (NASDAQ: SRAX) Releases Q4, FY 2021 Financial Report; Announces Partnership with Onassis Holdings (ONSS)

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (“SaaS”) platform, is reporting record financial numbers for fiscal year 2021 and Q4 2021. Highlights of the report show that SRA exceeded 2021 guidance of $31.5 million, totaling $28.6 million in revenue with BIGtoken, its former subsidiary, totaling $3.4 million in revenue, and record quarterly revenue of $9.6 million, a 27% increase from the company’s Q3 report and 170% over the previous year period. In addition, SRAX reported record GAAP operating income of $2 million in 2021 compared to a…

Continue Reading

MondayJun 06, 2022 12:45 pm

TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Adelia Has Reached Milestone Achievements

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced that Adelia Therapeutics Inc., its wholly owned subsidiary, has achieved significant milestones, which the company identified as Y2, Q2 (i), (vi), Y2, Q3 (ii), Year 2 Q4 (i) and Year 3 Q1 (i), (ii). These milestones are outlined in the Dec. 4, 2021, contribution agreement between Cybin and Adelia; the agreement specifies what actions are to be taken when these milestones are reached. Specifically, when these milestones are met, the agreement calls for class B common shares to be issued to Adelia shareholders; those shares are…

Continue Reading

FridayJun 03, 2022 2:55 pm

TinyGemsBreaks – SRAX Inc. (NASDAQ: SRAX) Announces Details for 2022 LD Micro Invitational

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, today announced details for the 2022 LD Micro Invitational. SRAX will host the prominent investor conference on June 7-9 at the Four Seasons Hotel Westlake Village, as well as via its Sequire Virtual Events platform. LD Micro is the host of the most influential conferences in the small-cap world. Following last October’s success of the LD Micro Main Event, SRAX is providing a virtual option for those unable to attend the physical conference. The event, which expects to…

Continue Reading

FridayJun 03, 2022 2:47 pm

TinyGemsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Announces Strong Q2 Financial Results

Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, today announced financial results for its second fiscal quarter ended April 30, 2022. Among the highlights, the company reported Q2 revenues of $8,482,743, a 221% increase as compared to the same quarter last year. The company also noted 15 consecutive quarters of profitability. “We are pleased with the financial results of our second quarter as a company with both B2B and B2C verticals,” said Golden Matrix CEO Brian Goodman. “During the quarter we implemented upgraded technology and stronger accounting controls to improve cash…

Continue Reading

FridayJun 03, 2022 2:25 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Awards Exclusive License to Japan’s Premier Wellness Science Co.

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has awarded licensing of its proprietary DehydraTECH(TM) offering for development in Japan to Premier Wellness Science Co. Ltd, a wholly owned subsidiary of Premier Anti-Aging Co. Ltd. LEXX announced that Premier is purchasing exclusive rights to DehydraTECH technology for the Japanese nonpharmaceutical market; the company will use the tech in oral liquid and nonliquid products, as well as for topical, hair-care, lip-care and cosmetics products. According to the announcement, Lexaria will receive minimum payments of $4,527,500 over the next five years, as all well as royalties from the sales of products…

Continue Reading

FridayJun 03, 2022 2:00 pm

TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) EMBARK Program Spotlighted in “Frontiers in Psychology” Article

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its proprietary EMBARK program is the focus of a recent article in the “Frontiers in Psychology” journal. The peer-reviewed article discusses the company’s model of psychedelic-assisted psychotherapy that integrates leading clinical approaches to promote effective facilitation and supportive healing with psychedelic medicines. Titled “Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model,” the article appears in the June 2, 2022, issue of the publication, which is the largest journal in the field of psychology. The article discusses EMBARK’s…

Continue Reading

FridayJun 03, 2022 1:39 pm

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) CEO to Appear on Benzinga’s ‘All Access’ Series

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, and its CEO and chair David Michery are spotlighted during an interview on Benzinga’s All Access Series. The interview is slated for today, June 3, 2022, at 11 a.m. ET. Michery and All Access host Spencer Israel will discuss the company, including its upcoming “Strikingly Different” U.S. test drive tour, which will include stops at 19 cities across the country. Benzinga’s All Access show is a valuable source for those who want to learn more about the latest-trending stocks and investment opportunities. The show features live CEO interviews, due diligence…

Continue Reading

ThursdayJun 02, 2022 1:38 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH Footprint Extends to Europe with License Granted to Valcon Medical

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has awarded licensing of its proprietary DehydraTECH(TM) offering for development in the European and United Kingdom markets. The company awarded the nonexclusive licenses to Valcon Medical A/S, a European contract manufacturing organization that specializes in the manufacturing of medical cannabis extracts for the EU and UK. According to the announcement, Lexaria will receive milestone fees and royalty payments from sales of products manufactured by Valcon.Valcon products will include an array of options, from nonregistered medical products through magistral programs to country-level market-authorized medical cannabis products through pilot programs; they will…

Continue Reading

Contact us: (512) 354-7000